BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the…
WASHINGTON, July 04, 2025 (GLOBE NEWSWIRE) -- Today, after President Donald J. Trump signed the One Big Beautiful Bill into law, Kelly Loeffler, Administrator of the U.S. Small Business Administration (SBA), released the following statement:
Washington, D.C., July 04, 2025 (GLOBE NEWSWIRE) -- As political debate intensifies over the cost and scale of President Trump’s sweeping legislative proposal—referred to by insiders as the “Big Beautiful Bill”—a released presentation by Jim Rickards suggests the U.S. government may already control the means to fund the majority of programs just like this internally.
Luxembourg – 4 July 2025 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of sizeable1 contract offshore Egypt. Subsea7 will be responsible for the engineering, procurement, commissioning and installation of flexible pipelines, umbilicals, and associated subsea components for a tie back to existing infrastructures.
NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION
Mon, 07 Apr 2025 01:00:00 GMT Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial ... All statements contained in this press release that do not relate to matters of historical ...
Sun, 06 Apr 2025 10:01:00 GMT Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity Company to host conference call on ...
Sun, 06 Apr 2025 10:01:00 GMT Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Monday, April 7, to discuss these clinical data. Participants may register for the conference call here. A ...
Sun, 06 Apr 2025 06:00:00 GMT Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial ... All statements contained in this press release that do not relate to matters of historical ...
Wed, 13 Nov 2024 13:31:00 GMT BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...
